Women over 65 years of age with early-stage, fast-spreading breast cancer had better chances of surviving if they endured treatment therapy, according to a new study.
Women over 65 years of age with early-stage, fast-spreading breast cancer had better chances of surviving if they endured treatment therapy, according to a new study.
Older women, including those who additional minor health problems, should undergo aggressive chemotherapy cancer treatments because these treatments will not only cure them, but also prevent the cancer from returning, according to researchers at the Duke Cancer Institute.
Gretchen Kimmick, MD, MS, an associate professor of medicine at Duke and the lead author of the study said that using chemotherapy for older women has always sparked controversy. Some resist the treatment because it is potentially toxic and too aggressive.
“However, this predictive model shows patients that they are going to survive long enough to see the benefit of treatment,” Dr Kimmick said.
Researchers assisting Dr Kimmick on the study included Brandelyn Pitcher, Jeanne Mandelblatt, Jonathan Clapp, Karla Ballman, Myra Barginear, Rachel Freedman, Andrew Artz, Heidi Klepin, Jacqueline Lafky, Judith Hopkins, Eric Winer, Clifford Hudis, Hyman Muss, Harvey Cohen, Aminah Jatoi and Arti Hurria.
The authors registered 2 groups of women aged 65 years and older for the trial—one group underwent chemotherapy treatment devised to prevent cancer recurrence and one group did not undergo the treatment. They used data from breast cancer studies in the Alliance for Clinical Trials in Oncology initiative funded by the National Cancer Institute.
The researchers then compared the daily routine between the 2 groups of women to evaluate the treatment and the quality-of-life issues. They traced their survival rates over a period of two years. They also considered their age and ability to perform daily tasks such as bathing and grocery shopping. This data was also fed into a popular online program called ePrognosis, a device used to measure the treatments against the individual’s potential lifespan.
The results were as follows:
Dr Kimmick said that with further research, they would be able to predict 5- and 10-year mortality risks. However, this study provides enough evidence to insist on getting cancer treatments for older women.
Doctors and researchers insist that prevention of cancer recurrence is as important, if not more, than treatment of cancer. Especially for older women, if the cancer relapses, the survival rate drops drastically and the quality of life worsens.
“Doctors and patients both need to understand the risks of cancer recurrence vs. chemotherapy and its side effects,” Dr Kimmick added. While it is important to note the risks of chemotherapy, it is equally important to consider the benefits of using the therapy to prevent cancer recurrence.
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More